文献速递冠心病心力衰竭与心肌病

ECMO-CS 随机临床试验:VA-ECMO 治疗心源性休克的结果

Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.
PubMed 文献 · Circulation · 2022-11-06

ECMO-CS 多中心随机试验纳入 117 例快速恶化或严重心源性休克患者,比较立即 VA-ECMO 与初始保守治疗(允许后续使用 VA-ECMO)。30 天复合终点在立即 VA-ECMO 组为 63.8%,保守组为 71.2%(HR 0.72,95%CI 0.46-1.12,P=0.21),差异无统计学意义。立即 VA-ECMO 未改善临床结局。

要点

  • 立即 VA-ECMO 未显著降低 30 天死亡、复苏后循环骤停或另置机械循环支持装置的复合终点。
  • 保守组 39% 患者后续使用了 VA-ECMO,两组全因死亡率、严重不良事件等无统计学差异。
  • 对快速恶化或严重心源性休克,可先采用保守治疗,病情恶化时再启用 VA-ECMO。

核心结论

  • 在快速恶化或严重心源性休克患者中,立即实施 VA-ECMO 与允许后续使用的早期保守策略相比,未改善临床结局。

研究设计与样本

  • 多中心、随机、研究者发起的学术临床试验,纳入快速恶化或严重心源性休克患者。
  • 随机分为立即 VA-ECMO 组或无立即 VA-ECMO 组,后者病情恶化时可后续使用 VA-ECMO。
  • 共 122 例随机,排除 5 例无知情同意后 117 例纳入分析,立即 VA-ECMO 组 58 例,无立即 VA-ECMO 组 59 例。

主要发现

  • 30 天复合终点(全因死亡、复苏后循环骤停、另置机械循环支持装置)在立即 VA-ECMO 组发生 37 例(63.8%),无立即 VA-ECMO 组 42 例(71.2%),HR 0.72(95%CI 0.46-1.12),P=0.21。
  • 无立即 VA-ECMO 组中 23 例(39%)后续使用了 VA-ECMO。
  • 30 天复苏后循环骤停发生率 10.3% 对 13.6%,风险差 -3.2(95%CI -15.0 至 8.5)。
  • 全因死亡率 50.0% 对 47.5%,风险差 2.5(95%CI -15.6 至 20.7)。
  • 严重不良事件发生率 60.3% 对 61.0%,风险差 -0.7(95%CI -18.4 至 17.0),脓毒症、肺炎、卒中、下肢缺血和出血两组无统计学差异。

临床怎么用

  • 对快速恶化或严重心源性休克患者,不应常规立即启动 VA-ECMO,可先给予标准保守治疗。
  • 保守治疗期间需密切监测血流动力学,病情恶化时再考虑启用 VA-ECMO。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used for circulatory support in patients with cardiogenic shock, although the evidence supporting its use in this context remains insufficient. The ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) aimed to compare immediate implementation of VA-ECMO versus an initially conservative therapy (allowing downstream use of VA-ECMO) in patients with rapidly deteriorating or severe cardiogenic shock. METHODS: This multicenter, randomized, investigator-initiated, academic clinical trial included patients with either rapidly deteriorating or severe cardiogenic shock. Patients were randomly assigned to immediate VA-ECMO or no immediate VA-ECMO. Other diagnostic and therapeutic procedures were performed as per current standards of care. In the early conservative group, VA-ECMO could be used downstream in case of worsening hemodynamic status. The primary end point was the composite of death from any cause, resuscitated circulatory arrest, and implementation of another mechanical circulatory support device at 30 days. RESULTS: A total of 122 patients were randomized; after excluding 5 patients because of the absence of informed consent, 117 subjects were included in the analysis, of whom 58 were randomized to immediate VA-ECMO and 59 to no immediate VA-ECMO. The composite primary end point occurred in 37 (63.8%) and 42 (71.2%) patients in the immediate VA-ECMO and the no early VA-ECMO groups, respectively (hazard ratio, 0.72 [95% CI, 0.46-1.12]; P=0.21). VA-ECMO was used in 23 (39%) of no early VA-ECMO patients. The 30-day incidence of resuscitated cardiac arrest (10.3.% versus 13.6%; risk difference, -3.2 [95% CI, -15.0 to 8.5]), all-cause mortality (50.0% versus 47.5%; risk difference, 2.5 [95% CI, -15.6 to 20.7]), serious adverse events (60.3% versus 61.0%; risk difference, -0.7 [95% CI, -18.4 to 17.0]), sepsis, pneumonia, stroke, leg ischemia, and bleeding was not statistically different between the immediate VA-ECMO and the no immediate VA-ECMO groups. CONCLUSIONS: Immediate implementation of VA-ECMO in patients with rapidly deteriorating or severe cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy that permitted downstream use of VA-ECMO in case of worsening hemodynamic status. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02301819.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ostadal, Rokyta, Karasek, et al. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation. 2022. PMID: 36335478. doi:10.1161/CIRCULATIONAHA.122.062949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。